Lana Pine

Multivariable models indicated that improvements in the physical component score and mental component score could be predicted by better self-efficacy scores in patients with systemic lupus erythematosus.

Patients with juvenile idiopathic arthritis were at a greater risk of developing autoimmune thyroid disease if they were female, reported ANA and/or RF positivity, and a family history of thyroid disease.

A recent study found that the biosimilar MSB11456 showed pharmacokinetic similarity, immunogenicity, and safety profiles comparable to the reference drug, tocilizumab, suggesting that it could be a cost-effective alternative for treating autoimmune disorders.

The clinician experience across specialties is crucial as the biosimilars market in the United States continues to expand.

Investigators evaluated the link between gout and thalassemia using data from Taiwan's Longitudinal Health Insurance Database 2000 (LHID 2000).

Of the 23 biomarkers identified in patients with gouty arthritis and hyperuricemia, kynurenic acid, thymine, and phosphatidylinositol (PI) differed from previous gout research.

Ginger Hultin, MS, RDN, explained the benefits of an anti-inflammatory nutrition plan for patients living with rheumatic and autoimmune conditions, as well as what rheumatologists need to know.

Compared with treatments like allopurinol, nanoparticles can improve the biocompatibility and bioavailability while reducing toxicity and side effects in patients with gout.

Results of a recent study indicated that when a patient is able to temper their underlying disease, it can improve their experience of centrally sensitized pain despite not obtaining low disease activity.

Roy Fleischmann, MD, examined the necessity of performing repeated x-rays in patients with rheumatic disease as a part of disease management.

Guselkumab, an interleukin-23 inhibitor, demonstrated sustained improvements in both TNF-naïve and TNF-experienced patients with psoriatic arthritis.

Pain, a key issue for patients with rheumatic diseases, is generally ranked as one of the top complaints of disease experience.

Philip Mease, MD, discusses other factors, besides drug inefficacy, that may impact pain in patients with rheumatic and autoimmune conditions.

Anisha Dua, MD, MPH, emphasized the looming workforce shortage, the challenges of attracting medical students to this field, and how practices changed during the COVID-19 pandemic.

Anisha Dua, MD, MPH, defines IgG4 and explains why IgG4-related disease is often difficult to diagnose, in part because it regularly affects a variety of organ systems.

Pharmaceutical claims data were collected for the reference drugs and etanercept and infliximab biosimilars to analyze changes in the proportions of dispensed of and total spending on biosimilars after the new start and biosimilar switching policies began.

Investigators noted that presenting tophi in perioperative patients was found to be an independent risk factor for gout recurrence within the first year postoperative.

As similar studies evaluating CT-P17 have not been conducted in Japan, these findings support applying the biosimilarity conclusions from other studies to this patient population.

Patients receiving guselkumab reported significant improvements in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months.

Electronic patient-reported outcome (ePRO) questionnaires may allow rheumatologists to better understand the patient's experience and monitor improvements over time.

The study utilized a nationwide cohort of patients with hemodialysis and peritoneal dialysis to evaluate gout prevalence, practice patterns, and clinical associations.

Investigators sought to analyze adherence, safety, and the clinical outcome in patients treated with the etanercept biosimilar, SB4.

Investigators hypothesized that patients with fibromyalgia who avoid activities because of pain would be more likely to perceive more intense pain levels after walking due to catastrophizing.

Despite multi-stakeholder information campaigns supporting the use of biosimilars, barriers remain that hinder uptake.

The systematic review compared mHealth interventions with conventional treatment or nonintervention to determine the pain management effects of mobile-based self-management strategies.

Results may help minimize the risk of developing hyperuricemia, gout, and related adverse events in patients receiving antihypertensive drugs.

Musculoskeletal ultrasound evaluated tophus size and double contour sign in lower extremity joints of patients with gout before and after initiating uric acid lowering therapy.

The DECT scoring system obtained excellent diagnostic performance for differentiating early-stage gout from middle-stage gout, with sensitivity, positive and negative predictive values, and specificity all achieving an accuracy of > 85%.

The majority of included studies observed improvements in pain, fatigue, patient global, sleep disturbance, multidimensional function, and tender points.

Anakinra effectively treated 94% of the gout flares included in the study sample and was a viable long-term treatment option.